Nuclea Biomarkers, LLC
Records under this name other than patents Nuclea Biomarkers, LLC holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 8 of 8 · Back to Nuclea Biomarkers, LLC
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US D598,548 | Stylet Term ended Term ended Aug 18, 2023 · High confidence | Term ended | Term ended Aug 18, 2023 | High confidence |
| US 7,897,354 | Kinase peptides and antibodies Lapsed on the fee record Ended Mar 1, 2023 · From the USPTO record | Lapsed on the fee record | Ended Mar 1, 2023 | From the USPTO record |
| US 7,763,438 | Gene and protein expression profiles associated with the therapeutic efficacy of irinotecan Lapsed on the fee record Ended Jul 27, 2022 · From the USPTO record | Lapsed on the fee record | Ended Jul 27, 2022 | From the USPTO record |
| US D530,021 | Antibody protein analysis chip Term ended Term ended Oct 10, 2020 · From the USPTO record | Term ended | Term ended Oct 10, 2020 | From the USPTO record |
| US 8,088,589 | Gene and protein expression profiles associated with the therapeutic efficacy of EGFR-TK inhibitors Lapsed on the fee record Ended Jan 3, 2020 · From the USPTO record | Lapsed on the fee record | Ended Jan 3, 2020 | From the USPTO record |
| US 9,029,512 | Anti-phospho-Akt antibodies Lapsed on the fee record Ended May 12, 2019 · From the USPTO record | Lapsed on the fee record | Ended May 12, 2019 | From the USPTO record |
| US 8,580,926 | Gene and protein expression profiles associated with the therapeutic efficacy of irinotecan Lapsed on the fee record Ended Nov 12, 2017 · From the USPTO record | Lapsed on the fee record | Ended Nov 12, 2017 | From the USPTO record |
| US 7,354,725 | Kinase peptides and antibodies Lapsed on the fee record Ended Apr 8, 2012 · From the USPTO record | Lapsed on the fee record | Ended Apr 8, 2012 | From the USPTO record |